Can a targeted antibody take on glioblastoma?
NCT ID NCT06632236
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants receive amivantamab weekly for the first month, then every two weeks, to see if it can shrink tumors or slow their growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amivantamab, an experimental antibody drug given by IV infusion
- What this could lead to
- If amivantamab proves safe and shows signs of shrinking or slowing these aggressive brain tumors, it could become a new treatment option for glioblastoma and similar cancers.
- What could go wrong
- This is an early, small phase 1 trial focused on safety and dosing, so it may not lead to a proven treatment. Amivantamab can cause infusion reactions and other side effects, and its effectiveness in brain tumors is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridge University Hospitals
Cambridge, CB2 0QQ, United Kingdom
-
The Royal Marsden Hospital - Drug Development Unit
Sutton, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- AI reads MRI scans to spot a deadly brain tumor type without surgery
- Brain cancer trial adds chemo pill to standard care
- Immune cells injected into brain to fight tumors
- New drug combo aims to tackle tough brain tumors in NF1 patients